Interferon alfacon-1

Last updated
Interferon alfacon-1
Clinical data
Routes of
administration 		Parenteral
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C860H1353N227O255S9
Molar mass 19241.16 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Interferon alfacon-1 is a interferon drug that is used to treat hepatitis C infections. [1]

Contents

Medical uses

In chronic hepatitis C, multiple phase II and III trials showed that subcutaneous interferon alfacon-1 produces dose-dependent reductions in serum HCV RNA, improves liver enzyme levels and histology, and yields sustained virologic responses broadly comparable to, and in some settings greater than those achieved with standard interferon-α. [2] In Japanese patients, Advaferon (interferon alfacon-1) demonstrated predictable pharmacokinetics, acceptable tolerability, and clinically meaningful antiviral efficacy, supporting its use as an alternative to conventional interferon-α preparations. [3]

Interferon alfacon-1 has also been evaluated for the treatment hairy cell leukemia, melanoma, and AIDS-related Kaposi's sarcoma, but has not been approved for these indications. [1]

Side effects

As a rationally designed interferon with higher specific antiviral activity, alfacon-1 has a safety profile consistent with expected interferon-related adverse effects (flu-like symptoms, cytopenias, neuropsychiatric effects and autoimmune phenomena), but lacks unique dose-limiting toxicities. It was a useful, [4] though now largely superseded by direct‑acting antivirals that target HCV proteins NS3, NS4A, NS5A and NS5B.

Mechanism of action

Interferon alfacon-1 is a synthetic “consensus” type I interferon engineered by aligning multiple human interferon-α subtypes and selecting the most common amino acids at each position. The resulting 166-amino-acid protein exhibits enhanced in vitro antiviral activity compared with several native interferon-α molecules. [1] It binds the type I interferon receptor and activates JAK-STAT signaling, inducing numerous interferon-stimulated genes that mediate antiviral, antiproliferative and immunomodulatory effects. These actions translate clinically into inhibition of hepatitis C virus replication and modulation of hepatic immune responses. [2]

References

  1. 1 2 3 DrugBank DB00069
  2. 1 2 Melian EB, Plosker GL (2001). "Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C". Drugs. 61 (11): 1661–91. doi:10.2165/00003495-200161110-00009. PMID   11577799.
  3. ↑ Yasuda S, Miyata K (December 2002). "[Interferon alfacon-1 (Advaferon): a novel synthetic interferon for the treatment of hepatitis C, its pharmacological and clinical profile]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 120 (6): 421–6. doi:10.1254/fpj.120.421. PMID   12528473.
  4. ↑ Witthöft T (December 2008). "Review of consensus interferon in the treatment of chronic hepatitis C". Biologics : Targets & Therapy. 2 (4): 635–43. doi: 10.2147/btt.s1852 . PMC   2727894 . PMID   19707444.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.